What's next for psychedelics after MDMA rejection?
Science (New York, N.Y.) August 16, 2024 DOI: 10.1126/science.ads4470 (opens in new tab) via PubMed
Summary
AI-generated from the abstractThe FDA's rejection of Lykos's application for a PTSD therapy using MDMA may push rival companies to change their business strategies, potentially speeding up a move toward different approaches in psychedelic medicine development.
Study at a glance
| Characteristics | Peer reviewed |
|---|---|
| Keywords | Psychedelic medicine Mental health treatments Pharmaceutical research Drug development Therapeutic compounds |
| Citations | 12 |
| Key finding | Lykos's failure to gain FDA approval for a PTSD therapy may accelerate strategic shifts among its competitors in the psychedelic medicine field. |
Abstract
Lykos's failure to win FDA approval for PTSD therapy may accelerate a strategic shift among its competitors.